NASDAQ:BCRX BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis $7.91 +0.26 (+3.35%) As of 01:05 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BCRX alerts:Sign Up Key Stats Today's Range$7.66▼$8.0050-Day Range$7.65▼$10.1752-Week Range$6.23▼$11.22Volume1.49 million shsAverage Volume4.88 million shsMarket Capitalization$2.02 billionP/E RatioN/ADividend YieldN/APrice Target$19.44Consensus RatingHold Company Overview BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options. BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets. Its development efforts have also included antiviral and other specialty-care programs, reflecting the company’s broader focus on small-molecule medicines for medically underserved patient populations.AI Generated. May Contain Errors. Read More BioCryst Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreBCRX MarketRank™: 3.37204591492 of 5 starsBioCryst Pharmaceuticals scored higher than 67% of companies evaluated by MarketBeat, and ranked 236th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingBioCryst Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on no strong buy ratings, 6 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialBioCryst Pharmaceuticals has a consensus price target of $19.44, representing about 144.7% upside from its current price of $7.95.Amount of Analyst CoverageBioCryst Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioCryst Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($2.28) to $0.72 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCryst Pharmaceuticals is -5.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCryst Pharmaceuticals is -5.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioCryst Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.18% of the float of BioCryst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverBioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 4.62.Change versus previous monthShort interest in BioCryst Pharmaceuticals has recently decreased by 21.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioCryst Pharmaceuticals does not currently pay a dividend.Dividend GrowthBioCryst Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.51 News SentimentBioCryst Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for BioCryst Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest17 people have searched for BCRX on MarketBeat in the last 30 days. This is an increase of 240% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders3.80% of the stock of BioCryst Pharmaceuticals is held by insiders.Percentage Held by Institutions85.88% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioCryst Pharmaceuticals' insider trading history. Receive BCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCRX Stock News HeadlinesBioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by Wall Street ZenOctober 24 at 1:13 AM | americanbankingnews.comBioCryst to Report Third Quarter 2026 Financial Results on November 4October 21, 2026 | globenewswire.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 26 at 1:00 AM | Weiss Ratings (Ad)BioCryst Wins FDA Approval For Orladeyo Oral Pellets In HAE Patients Aged 12 And OlderOctober 21, 2026 | rttnews.comBioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAEOctober 21, 2026 | globenewswire.comHead-To-Head Review: Syndax Pharmaceuticals (NASDAQ:SNDX) & BioCryst Pharmaceuticals (NASDAQ:BCRX)October 21, 2026 | americanbankingnews.comContrasting Compass Therapeutics (NASDAQ:CMPX) & BioCryst Pharmaceuticals (NASDAQ:BCRX)October 19, 2026 | americanbankingnews.comBioCryst (BCRX) Trades at Just 11x Forward Earnings. Is the Market Pricing In Trouble?October 15, 2026 | insidermonkey.comSee More Headlines BCRX Stock Analysis - Frequently Asked Questions How have BCRX shares performed this year? BioCryst Pharmaceuticals' stock was trading at $7.80 at the beginning of 2026. Since then, BCRX stock has increased by 1.9% and is now trading at $7.9450. How were BioCryst Pharmaceuticals' earnings last quarter? BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) issued its quarterly earnings data on Wednesday, August, 5th. The biotechnology company reported $0.30 EPS for the quarter, topping analysts' consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals's quarterly revenue was up 33.6% compared to the same quarter last year. Read the conference call transcript. Who are BioCryst Pharmaceuticals' major shareholders? Top institutional shareholders of BioCryst Pharmaceuticals include Assenagon Asset Management S.A. (0.18%), Inspire Investing LLC (0.14%), Doliver Advisors LP (0.12%) and Councilor Wealth LLC (0.02%). Insiders that own company stock include Alane P Barnes, Helen M Thackray, Anthony Doyle, Nancy J Hutson, Theresa Heggie, Steven K Galson, Alan G Levin, Amy E Mckee, Machelle Sanders and Steve Aselage. View institutional ownership trends. How do I buy shares of BioCryst Pharmaceuticals? Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioCryst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioCryst Pharmaceuticals investors own include Palantir Technologies (PLTR), Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Micron Technology (MU), Marvell Technology (MRVL) and Novavax (NVAX). Company Calendar Last Earnings8/05/2026Today10/26/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 13 days, BCRX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BCRX CIK882796 Webwww.biocryst.com Phone(919) 859-1302Fax919-859-1314Employees435Year Founded1986Price Target and Rating Average Price Target for BioCryst Pharmaceuticals$19.44 High Price Target$32.00 Low Price Target$9.00 Potential Upside/Downside+143.5%Consensus RatingHold Rating Score (0-4)2.45 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$263.86 million Net Margins-40.90% Pretax Margin-40.53% Return on Equity-86.89% Return on Assets66.37% Debt Debt-to-Equity RatioN/A Current Ratio2.32 Quick Ratio2.29 Sales & Book Value Annual Sales$874.84 million Price / Sales2.33 Cash Flow$1.29 per share Price / Cash Flow6.18 Book Value($0.57) per share Price / Book-14.01Miscellaneous Outstanding Shares255,540,000Free Float245,825,000Market Cap$2.04 billion OptionableOptionable Beta0.55 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:BCRX) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredBeginner’s Guide to GoldInflation, trade wars, and market volatility have many savers rethinking how they protect retirement funds. A ...Goldco Direct, LLC | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredAnd they say the headline number understates what’s really happening.Goldman Sachs just admitted it underestimated central bank gold purchases by more than 500 percent, with buyin...Cedar Gold Group | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
